Núñez Julio, Miñana Gema, Núñez Eduardo, Chorro Francisco J, Bodí Vicent, Sanchis Juan
Servicio de Cardiología, Hospital Clínico Universitario, INCLIVA, Universitat de Valencia, Avda. Blasco Ibáñez 17, 46010, Valencia, Spain,
Heart Fail Rev. 2014 Sep;19(5):575-84. doi: 10.1007/s10741-013-9402-y.
In recent years, there has been a proliferation of new biomarkers with potential prognostic implication in heart failure (HF). Nevertheless, most of them do not fulfill the required criteria for being used in daily clinical practice. Tumor marker antigen carbohydrate 125 (CA125), a glycoprotein widely used for ovarian cancer monitoring, is synthesized by epithelial serous cells in response to fluid accumulation and/or cytokine stimuli. This glycoprotein has been emerged as a potential biomarker in HF. Plasma CA125 correlates with clinical, hemodynamic, and echocardiographic parameters related to the severity of the disease. High levels have shown to be present in the majority of acutely decompensated patients, and in this setting, it has shown to be independently related to mortality or subsequent admission for acute HF. In addition, certain characteristics such as wide availability and the close correlation between plasma changes with disease severity and clinical outcomes have increased the interest of researchers about the potential of this glycoprotein for monitoring and guiding therapy in HF. In this article, we have reviewed the available evidence supporting the potential role of CA125 as a biomarker in HF.
近年来，出现了大量对心力衰竭（HF）具有潜在预后意义的新生物标志物。然而，其中大多数不符合日常临床实践中使用的必要标准。肿瘤标志物抗原糖类125（CA125）是一种广泛用于监测卵巢癌的糖蛋白，由上皮浆液细胞在液体蓄积和/或细胞因子刺激下合成。这种糖蛋白已成为HF中的一种潜在生物标志物。血浆CA125与疾病严重程度相关的临床、血流动力学和超声心动图参数相关。大多数急性失代偿患者的CA125水平较高，在这种情况下，它已被证明与死亡率或随后因急性HF入院独立相关。此外，诸如广泛可得性以及血浆变化与疾病严重程度和临床结局之间的密切相关性等某些特征，增加了研究人员对这种糖蛋白在HF监测和指导治疗方面潜力的兴趣。在本文中，我们综述了支持CA125作为HF生物标志物潜在作用的现有证据。
